Wex Pharma----TopChance 2006 - 500 Beiträge pro Seite

[BrauchGeld]

Moin

Eine neue perle aus Canada mit enormes Potential.
Wenn die Aktie etwas bekannter wäre,würde Wex Pharma bestimmt um einiges höher notieren.
Wex Pharma besitzt ein äusserst interessantes produkt(Tectin) das aus Kugelfisch gewonnen wird :Klinischer Einsatz als Schmerzmittel bei Krebspatienten im Endstadium
klinische Phase II/III
keine Nebeneffekte wie Morphin, keine Wechselwirkungen mit
Medikamenten, macht nicht abhängig
~3200x stärker als Morphin
urspünglich entwickelt, um Entzugssymptome (Heroin) zu mildern.
Phase II/III interim analyse für März/April und Zulassungsantrag für ende 2006 geplant.
Für Tectin beträgt der Markt über 13 Mrd$ und Wex Pharma hat sehr gute chancen sich davon ein grosses stück ab zuschneiden.
Diese Aktie besitzt brutales Potential und wer mutig ist kann von anfang an dabei sein,für mich das beste Investment neben Ym Bioscience aus Canada.

Wex Pharma
Kurs:1,70 C$ // 1,24€
Marktkap:59,6 c$ // 43,3€
Shares Out:35 mio

Homepage:
http://www.wextech.ca/



Stock of the Week (11.02.2006):
http://stockhouse.ca/bullboards/wraplink.asp?url=miningstock…

Recommendation - We continue to recommend holding WEX Pharmaceuticals in your portfolio. Although the
price has appreciated by ~155% since 1999, we did not anticipate just how long it would take to move this
impressive product to approval. If you have not yet added WEX to your portfolio, we recommend doing so
now. We waited to do our year end summary because there have been some very significant management
changes and a special shareholder meeting held on January 26, 2006. We wanted to see resolution of these
issues before updating you. It is obvious from looking at the last seven days of trading, that the changes are
regarded very positively by investors.
Since WEX now appears to be on the home stretch with respect to gaining Health Canada approval, we would
not be surprised if this company was worth several times its current price by the end of 2008. In simple terms,
WEX would be over a billion dollar company (in terms of gross revenue) if it captured just 10% of only the late
stage cancer pain management market ($13.3B). Keep in mind that statement was made only on the basis of the
application of this company’s platform drug for this very narrow piece of the pain market. Longer term
applications not only for much lager markets dealing with other pain applications, but also for the treatment of
opiate addition on a global scale, hold the promise for even larger scale revenues longer term. We would always
add the caution that no company can guarantee that their product will gain government approval.
Company Business - Before we go into those management changes, we would like to take the opportunity to
review for you what WEX does. It is probably the most unusual stock recommendation in our portfolio (in
terms of what their product is). From their website:

“WEX Pharmaceuticals Inc. is a development stage (neuro bio-science) pharmaceutical company
focused on the creation and commercialization of innovative drug products, primarily for pain
management. WEX`s lead compound, Tetrodotoxin (TTX), is the platform for the Company`s
development of a portfolio of proprietary products in the field of analgesia, drug addiction
withdrawal treatment, and local anesthesia. Tetrodotoxin, a naturally-occurring sodium channel
blocking compound found primarily in the fugu or puffer fish, is used to address pain. TTX has the
characteristic of being non-opioid (non-addictive), up to 3200 times stronger than morphine and
with only mild to moderate reversible side effects.”

“The Company’s principal business strategy is to derive drugs from naturally occurring toxins and
develop proprietary products for certain markets. The Company also generates ancillary revenues
from sales of generic products manufactured at its facility in China.”
WEX Proprietary Compounds – WEX is currently devoting most of its resources to gain Health Canada and
US FDA approval for
Tectin™. However, they describe two additional TTX platform products that show a great deal of potential in
two other applications:
· “Analgesia - Tectin™, for inadequately controlled (late stage) cancer pain. The Phase IIa analysis
showed Tectin™ to be meaningful as it relieved chronic pain in 71% of cancer pain patients. WEX
has a Phase IIb/III pivotal trial in Canada underway. WEX has also been cleared to begin a
Canadian trial for severe non-malignant chronic pain and has started a Phase II analgesic study in
China.
· Detoxification - Tetrodin™, for the treatment of opioid withdrawal symptoms.
· Anaesthesia - Tocudin™, for dental care, is in pre-clinical studies.”
Tectin™ - The product that WEX is focusing on moving through Health Canada and US FDA approval is
Tectin™. Indications are that Tectin™ is extremely effective in managing pain, is not addictive and does not
cause drowsiness. Frequently, severe chronic pain is not alleviated by over the counter products. Prescribed
narcotic pain medications such as morphine are addictive and cause drowsiness. Compassionate use of
morphine for late stage cancer patients relieves pain, but causes individuals to sleep most of the time rather than
being able to enjoy family and friends in their last days. Using narcotic medications for relieving non-terminal
severe and chronic pain (e.g., accidents, surgery, arthritis, etc.) has a high risk of addiction.

One of the intriguing things about Tectin™ is its source. Tectin™ is derived from an extremely potent toxin
called Tetrodotoxin that resides in some species of the puffer fish. Puffers look like a normal fish until they are
threatened, at which point, they pull enough water in their stomachs to blow themselves up into an almost
spherical shape (see the photos below). They basically look like an underwater basketball with fins. The
unlucky predator choosing to make a meal out of a puffer digests a fish with a neurotoxin that is 1200 times
more potent than cyanide. The source of the toxin is actually from bacteria that are in food that the puffer fish
eats. That neurotoxin is called Tetrodotoxin and is found in particularly high concentrations in certain parts of
the fish. In Japan, the puffer is called “fugu,” and is an extremely expensive delicacy that can only be prepared
by licensed chefs.

Now that we have your undivided attention, we will describe WEX’s progress and technology in creating what
we think will be a blockbuster product. While Tetrodotoxin is extremely toxic, WEX has found that their
patented compound Tectin™, in very small amounts, relieves pain very effectively. There are other products
that relieve pain, but we know of no others that do so while leaving the person fully alert and ready to enjoy life.
Additionally, we know of no others that relieve pain as effectively with no risk of addiction. Even more
impressive, trials have shown a lasting pain relief not offered by other products. Patients get a subcutaneous
injection of Tectin™ (30 mg.) one time per day for four days and then wait for two weeks before another four
days of injections. Suffice it to say there are few if any products that provide pain relief lasting for two weeks.
Its mechanism is sodium channel blocking. Tetrodotoxin (the puffer toxin) does NOT cross the blood brain
barrier, which is why it leaves an individual fully conscious even when completely paralyzed by relatively large
amounts of the puffer neurotoxin. This characteristic is why WEX’s low dose (30 mg.) Tectin™ product
relieves pain, but leaves even terminal cancer patients fully conscious, alert and able to enjoy interacting with
their family and their environment.

Health Canada Clinical Trials and Approval - The significance of their current Canadian Phase IIb/III
pivotal trial of Tectin™ should be noted. There is NO separate Phase III trial. This is the last stage of clinical
trials prior to a request for approval by Health Canada. There will be 146 patients enrolled in this phase
(double blind), and the study has already enrolled over half (~80) of those. WEX expects an interim analysis to
be completed by the end of March. Full results will not be announced, but the committee reviewing those
results will provide a recommendation which will be released. Their recommendation will be one of the
following: 1) Continuing the Tectin™ study; 2) continuing the study with possible recommendations for
changes; or 3) Cessation of the study. In conversations with the company, it is clear that they do not expect the
committee to recommend terminating the study. We hesitate to put estimated dates for completion of the study,
the statistical analysis, and the preparation of the NDA, but WEX expects to gain Health Canada approval prior
to the end of 2007. It appears as though it is not unusual for Health Canada to take 12-24 months to make a
decision for approval. However, WEX will have “accelerated approval” (not the same as U.S. FDA “fast
track”). Approval is evidently expedited to 9-12 months for a product that meets an unmet medical need, in this
case, pain management for late stage cancer patients.
US FDA Approval - WEX is not currently testing any compounds in the U.S. However, U.S. FDA approval
has a high priority. It is their intention to file an Investigational New Drug (IND) application with the FDA in
March or April of 2006. An IND is the submission of a proposed clinical testing protocol and a request to
conduct those tests in the U.S. It will take approximately 30 days for approval. It is possible that patients could
begin dosing in the US by mid-summer or early fall. After clinical testing is completed, WEX intends to file for
FDA approval with an objective of obtaining FDA approval prior to the end of 2008. We would caution that we
have not heard of any situation where any kind of governmental approval for a prescription drug takes less time
than expected. If there are any changes to expected time frames, they always seem to take longer.

Management Changes – WEX’s website provides a concise history of the company. Frank Shum founded the
early company and over a dozen years ago, created a joint venture with a Chinese pharmaceutical company
which had been doing research on using Tetrodotoxin (TTX) to relieve addictive substance withdrawal
symptoms. Continued research indicated that TTX was a powerful painkiller. To make a longer story short, the
company continued successful clinical work, but arrived at the point that many emerging companies do in that
they needed to make some management changes to move the company and the product forward expeditiously.
WEX got a new Chairman of the board in April of 2005. In August of 2005, Frank Shum stepped down as the
CEO but remains with WEX as President of Asian Operations to concentrate on the Company`s interests in
Asia. On December 20, 2005, WEX named a new President and CEO, Dr. Edge Wang. Dr. Wang’s bio is
posted on the website under “Management.” We would encourage you to read it. His experience is broad and
his education impressive. If we began to list his many relevant qualifications for this job, we would only be
repeating what is there. Suffice it to say that it appears that they have found a man with an incredibly broad
package of skills, management expertise and talent to continue to move WEX forward. The same news release
announced the hire of several other imminently qualified WEX management team members. In December of
2005, Mr. Simon Anderson, a chartered accountant joined the Board of Directors. He has over 19 years of
experience which included corporate finance, financial consulting, mergers and acquisitions and securities
markets valuation. WEX’s January 27, 2006 news release announced that Benjamin Chen, Pierre Cantin and
A.J. Miller were elected as directors. These gentlemen all have varied and extensive qualifications (see the
news release) that will provide invaluable relevant expertise as WEX moves forward. One of the things an
emerging company needs is interest from the institutional side of the investment community. Past feedback
from institutions indicated their desire to see a stronger board with more experience. The company feels that
these new directors and full time management team members will provide WEX with the relevant experience
needed to attract institutional investment.

There were no less than 35 news releases in 2005. Sixteen of those releases had to do with management
changes and with a special shareholder meeting requested by shareholders. We do regard the many news
releases as very positive on the part of WEX. It is an indication of their desire to be open and as transparent
with shareholders as regulations allow them to be. WEX released the issues related to management changes
along with continuing to post the positive results of clinical trials. Taking any small and emerging company
through a transition like this is normally very difficult for many reasons. Investors do not like the disruption and
uncertainty that it can bring. That is evident when you look at a two year WEX chart that shows a relentless
slide in the stock price. The good news is that the slide stopped in early fall of last year. A nice rally ensued
and was probably stopped with the news of a requested special shareholder meeting. Since early January, the
stock has moved about 75% off its lows, formed a double bottom and we think is poised to continue its rally.
Conclusion -There is much more information available on the website that we just cannot address in this
already lengthy summary. At a minimum, we encourage subscribers to read the extensive information available
on the WEX website prior to investing. In short, we believe WEX has turned a corner with management
changes and additions. Investor approval for that aspect has already been indicated in the chart. They are
approaching the end of their final phase of clinical testing in the cancer pain indication. The recommendation
resulting from the interim analysis is expected to be positive and will be an important indication of the
effectiveness of Tectin™. That is an extremely important (and positive) milestone for any pharmaceutical
company and we would expect the stock price to respond positively. WEX plans on seeking additional capital
in Q2 of this year. In order to gain as much leverage as possible, they are likely to make relevant and
appropriate releases to enhance the value of the company in the near term. We expect that their efforts to
enhance the value of the company in the next six months will significantly enhance the value of your shares.
We would encourage you to use corrections to add to positions in these share and of course as always we
suggest not allocating more than 5% of your entire portfolio to this one stock.

[BrauchGeld]

Wex Pharma target price C$5
Jennings

[BrauchGeld]

Für den Europäischen Markt gibts schon einen Partner :

WEX has developed a strategic alliance with Laboratorios Dr. Esteve S.A. of Barcelona, Spain providing approx. Cdn$60M in milestone payments and European clinical trial registration costs. WEX plans to develop additional strategic alliances with established pharmaceutical companies worldwide. Our partners will share the cost of late stage drug development and will market our products into their territories.


Hübscher Fisch:

[BrauchGeld]

Ich hab ein gutes gefühl das Wex der nächste Highflyer wird nach Cipher Pharma und Ym Bioscience.

WEX Reports Third Quarter Results

VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - Feb. 16, 2006) - WEX Pharmaceuticals Inc. ("WEX" or the "Company") (TSX:WXI) reported highlights and financial results for the three and nine months ended December 31, 2005. All amounts, unless specified otherwise, are in Canadian dollars.
Third Quarter Highlights

- Dr. Edge Wang was named President and Chief Executive Officer of the Company.

- The Company completed enrolment and dosing of 50% of the patients in the TectinTM Phase IIb/III clinical study. The Company is preparing an interim analysis which is expected to be completed in March 2006.

- The Company announced the preliminary results of its Chinese Phase IIa clinical trial of TectinTM. There were no serious adverse side effects reported at any dose level. The results seem to demonstrate an efficacy optimal dose similar to that identified within the Canadian development.

- The Company received a positive response from the U.S. Food and Drug Administration (FDA) in regard to the Chemistry, Manufacturing and Controls (CMC) section of its upcoming Investigational New Drug Application (IND) dossier for TectinTM. The FDA indicated that they have no concerns with the CMC at this time and now the Company will move ahead with an IND filing in the US

- Mr Simon Anderson and Dr. Howard Cohen joined the Board of Directors to replace Michael Chen who had resigned and Dr. Phil Gold who had stepped down and will serve the Company as a member of the scientific advisory board.

Subsequent Event

- On January 26, 2006 the Company held a special shareholders meeting to vote on two resolutions brought forward by a shareholder. During the meeting Frank (Hay Kong) Shum and Donna Shum were removed as directors of the Company and Benjamin Chen, Pierre Cantin and A.J. Miller were elected as directors to replace Frank (Hay Kong) Shum and Donna Shum and to fill the vacancy which resulted from Kenneth Li`s resignation. The Shareholder`s proposal on the creation of a royalty trust was defeated.

Financial Results - Unaudited

For the three months ended December 31, 2005, the Company recorded a loss of $5,794,556 ($0.17 per common share) compared to a loss of $4,502,411 ($0.13 per common share) in the three months ended December 31, 2004. The increase in loss for the three months ended December 31, 2005 is mainly attributable to increased clinical trial costs, legal costs related to the special shareholder meeting held on January 26, 2006, and a non-cash expense of $830,516 due to a revaluation resulting from the amendments of the payment terms of the debentures now requiring full repayments up to December 31, 2007.

The Company recorded a loss for the nine months ended December 31, 2005 of $13,427,026 ($0.38 per common share) compared to a loss of $10,231,725 ($0.32 per common share) in the nine months ended December 31, 2004. The increase in loss for the nine months ended December 31, 2005, when compared to the preceding period, is attributable to the large increase in clinical trial costs, legal costs, and the non-cash expenses for the settlement of debentures.

Management expects losses to continue during the coming quarters as it continues to focus resources on clinical trials in an effort to further the commercialization of TectinTM.

The Company had cash, cash equivalents and short term investments of $12,157,952 as at December 31, 2005 as compared to $20,814,464 as at March 31, 2005. Working capital as at December 31, 2005 was $7,692,361 as compared to $22,014,096 as at March 31, 2005. The Company is planning a new financing to strengthen its financial position.

[Zentimeter]

danke für den Tipp brauche Geld

aber denke dran Transition gehört auch ins Depot



Die Kanadier begreife ich net müssen sich mal am Techdax listen lassen

[BrauchGeld]

Diese Aktie ist natürlich nichts für schwache nerven hier heisst es alles oder nichts high risk eben.
Was mich etwas positiv stimmt ist ,das bald eine finanzierung geplant ist aber erst nach der veröffentlichung der ergebnisse.
Sollte Wex erfolgreich sein mit Tectin dann wird dieses produkt garantiert ein Blockbuster und deshalb bin ich investiert.

In ca. 4o tagen wissen wir mehr also daumen drücken und zittern.

[Zentimeter]

39 Tage noch?



habe aber ein gutes Gefühl

naja bin dabei

[Zentimeter]

aktuell tut sich net viel leicht abwärts, kaum Umsätze

gelegentlich OLT Orders

hoffe mal dass das aufgeht

[BrauchGeld]

Manchmal wird viel mut auch hart bestraft

WEX Pharmaceuticals Inc.: Tectin`TM` Phase IIb/III Interim Analysis
Sunday March 5, 11:00 pm ET


VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - March 5, 2006) - WEX Pharmaceuticals Inc. ("WEX" or the "Company") (TSX:WXI - News) today announced the recommendation of the Data Monitoring Committee ("DMC") following an interim analysis of its Canadian Phase IIb/III clinical trial of Tetrodotoxin (Tectin(TM)), an investigational drug for the management of cancer-related pain.

The trial is a multi-center, double-blind, randomized, placebo-controlled, parallel designed trial to assess the efficacy and safety of Tectin(TM) for inadequately controlled, moderate to severe cancer-related pain. The interim analysis was performed after 73 patients (half the projected total patient sample size) were enrolled and completed the study. The primary objective of the DMC was to evaluate the unblended results on the primary efficacy outcome, review the safety data and make recommendation to the trial sponsor regarding continuation or early termination of the study based on a conditional power approach. The DMC did not have any serious concern about the safety profile of Tectin(TM). The results of the primary efficacy outcomes demonstrated unfavourable results leading to the recommendation to terminate the current Phase IIb/III trial.

The Company will thus halt the future enrolment of patients at all the study sites of the current Phase IIb/III trial and proceed to a detailed analysis of the results with the objective to identify a subset of patients who could potentially benefit from the drug. Results of this analysis will also serve to adjust the Tectin(TM) development plan whereby the cancer-related pain strategy could be modified as well as other types of pain could become new targets for future trials.

"We are obviously disappointed by the recommendation following this interim analysis but will evaluate further the study data to increase our knowledge on the pharmacology of Tectin(TM) and identify new opportunities," said Dr. Jean Bourgouin, Chief Medical Officer of the Company.

"The unexpected recommendation following the interim analysis of Tectin(TM) Phase IIb/III study is a temporary setback for the company. However, I remain confident that we have the right product platform for a pain therapeutic that addresses a significant unmet medical need and that targets a key segment of the large pain market. A full review of the data, supported by clear scientific rationale, will help us in the design of clinical protocols for planned future studies, including a planned study under a US IND," said Dr. Edge Wang, Chief Executive Officer of the Company. "I believe that our European partner will also benefit from the interim results in the design of our European trials."

The Company will further control its spending by reducing its workforce and taking additional measures to extend the financial resources to allow the continued development of the Company`s lead product candidate Tectin(TM).

[Zentimeter]

na Mahlzeit



darum fiel der Kurs und die große Stückzahl im bid

[Zentimeter]

nja die Pleite ist es nun net

aber das agressive Potential ist erstmal weg

[Zentimeter]

jetzt versteht man den Namen BrauchGeld

[Zentimeter]

ich verkaufe net

manche legen es auf die hohe Kante

ich lege es als Leiche in den Keller, ist ne Rentenvorsorge

[BrauchGeld]

Ich hab von anfang an gesagt das es sich hier um eine gefährliche investition handelt ,wer in Biotech investiert muss mit sowas rechnen.
Naja ich war etwas vorsichtig mit umgerechnet 1500€ minus kann ich gut leben hab schlimmeres befürchtet.

Meine grössten Biotech Pleiten in den letzten 8-10 jahren:

Inex Pharma
Inflazyme
Cv Therapeutics
Vertex Pharma

Insgesamt läuft es aber doch sehr gut ,ich riskiere gerne was und bisher hat es sich meistens ausgezahlt .
Ich stelle mir einfach vor ich hätte mir für dieses Geld ein LCD Flachbildschirm gekauft

[Zentimeter]

nach unten ist da kein Platz mehr

habe noch nie so eine bid Kraft gesehen nach einer Horrornews

einige wissen mehr, aber zu einem weiteren Kauf kann ich mich net durchringen, denke das Investment ist schneller im + als wir denken

SPPI kurz vor Explosion

[Zentimeter]

fällt ja wieder großes bid erstmal weg, wer war da so heiss auf die Aktie?

[Zentimeter]

schätze den aktuellen Wert der Firma auf ca. 1 CAD pro share

könnte mir eine Übernahme zwischen 100 Millionen bis 200 Mllionen CAD vorstellen

langfristig immernoch tenbagger Chancen

[Zentimeter]

für mich ein Punkt den man bei 0,5 CAD nicht überlesen sollte:
“The unexpected recommendation following the interim analysis of Tectin™ Phase IIb/III study is a temporary setback for the company. However, I remain confident that we have the right product platform for a pain therapeutic that addresses a significant unmet medical need and that targets a key segment of the large pain market. A full review of the data, supported by clear scientific rationale, will help us in the design of clinical protocols for planned future studies, including a planned study under a US IND.” said Dr Edge Wang, Chief Executive Officer of the Company. “I believe that our European partner will also benefit from the interim results in the design of our European trials.”
The Company will further control its spending by reducing its workforce and taking additional measures to extend the financial resources to allow the continued development of the Company`s lead product candidate Tectin™.

Fazit:
ich werde gering aufstocken

[Zentimeter]

großes Kompliment an den Schnäppchenjäger von Berlin

Liest du hier?

Hat sich 2500 Stück zu 0,31 Euro in Berlin geschnappt
Arbitrage 25 Prozent

stark

tja ich mußte mich dann mit 0,35 abspeissen lassen
Arbitrage 6 Prozent

[Zentimeter]

ich vermute diese Woche oder nächste Woche
Kurse um 0,7 CAD ohne news

[Zentimeter]

noch etwas am Rande was durch die Horrornews in Vergessenheit geraten ist:
Market:
In 2003 world-wide analgesic drug sales totaled US $43B of which cancer pain drug sales accounted for US13.3B and neuropathic pain for US2.4B. Detoxifacation drug sales totaled US$7.8B and anesthetic drug sales totaled US$2.7B.

Intellectual Property:
WEX currently has 82 patents filed or granted governing its product process, application and formulation in up to 63 countries.

----------
WEX plans to develop additional strategic alliances with established pharmaceutical companies worldwide. Our partners will share the cost of late stage drug development and will market our products into their territories.
-----------
ca. 10 Millionen cash
----------
About WEX Pharmaceuticals Inc.



WEX Pharmaceuticals Inc. is dedicated to the discovery, development, manufacture and commercialization of innovative drug products to treat pain. The Company’s principal business strategy is to derive drugs from naturally occurring toxins and develop proprietary products for the global market. The Company’s Chinese subsidiary sells generic products manufactured at its facility in China.

---------
The Company is planning a new financing to strengthen its financial position.

[Zentimeter]

Bodenbildung ist abgeschlossen 0,465 CAD
leider habe ich ein paar Pünktchen früher schon mein Investment abgeschlossen

jetzt ist erstmal Platz bis ca. 0,59 CAD